TTK Healthcare Limited Reports FY26 Results

TTK Healthcare Limited reported revenue from operations of ₹857.28 crore for the financial year ended March 31, 2026, a 6.96% increase from ₹801.49 crore in FY25. However, the company's net profit saw a significant decline of 19.56%, falling to ₹65.68 crore from ₹81.66 crore in the previous fiscal year.

Reader Takeaway: Revenue growth is positive, but profit decline due to exceptional items and segment loss needs investor attention.

What just happened

TTK Healthcare announced its financial results for the fiscal year ended March 31, 2026. While revenue from operations grew by 6.96% to ₹857.28 crore, the net profit after tax (PAT) decreased by 19.56% to ₹65.68 crore. This drop in profitability was primarily due to a net exceptional charge of ₹4.07 crore in FY26, contrasting with an exceptional income of ₹13.91 crore in FY25. The company also recommended a dividend of ₹10 per equity share (100% payout).

Why this matters

The divergence between revenue growth and profit decline highlights potential cost pressures or one-off events impacting the bottom line. Investors will be keen to understand the factors driving the profit reduction, especially the impact of exceptional items and the performance of specific business segments.

The backstory

In the previous fiscal year, FY25, TTK Healthcare had reported a net profit of ₹81.66 crore on revenues of ₹801.49 crore. The current year's results show a struggle to maintain profitability despite topline expansion, signalling a need for operational efficiency improvements or a different business mix.

What changes now

Investors need to reassess the company's profitability outlook given the drop in PAT. The recommended dividend offers some return, but the underlying operational performance, particularly in the Protective Devices segment, which reported a loss of ₹10.54 crore, will be crucial for future stock performance.

Risks to watch

The primary risk identified is the loss incurred by the Protective Devices segment, which acts as a drag on overall profitability. Additionally, the impact of exceptional items on year-on-year profit comparability needs careful analysis by investors.

Peer comparison

(No specific peer comparison data provided in the filing.)

Context metrics (time-bound)

• Revenue from Operations: ₹857.28 crore in FY26 vs. ₹801.49 crore in FY25 (+6.96%).
• Net Profit (PAT): ₹65.68 crore in FY26 vs. ₹81.66 crore in FY25 (-19.56%).
• Basic EPS: ₹46.48 in FY26 vs. ₹57.79 in FY25 (-19.57%).
• Dividend Recommended: ₹10 per equity share (100%) for FY26.

What to track next

Investors should closely monitor the turnaround efforts in the Protective Devices segment and the company's ability to manage exceptional items and sustain margins across its other business verticals. The reappointment of Mr. T T Raghunathan as Executive Chairman for a further term of 5 years provides leadership continuity.